VerteGlide Targets OrthoPediatrics’ $19.2 Million Scoliosis Revenue
Key Facts
OrthoPediatrics announced the full commercial launch of VerteGlide on November 9, 2026, but the launch statement confirming the development could not be verified. Details of the announcement or its rationale therefore cannot be confirmed, including the claim that the transition followed successful results and strong demand during an initial phase. The system’s context is based on U.S. Food and Drug Administration approval, which limits its use to a group of children under 10 years old. The group includes skeletally immature patients with remaining spinal growth who need early correction of severe, progressive and life-threatening deformity. Cases include early-onset scoliosis when accompanied by, or at risk of, thoracic insufficiency syndrome. This indication places the system in a defined clinical segment, while the effect of the announced commercial launch on sales cannot be assessed from the available information.
VerteGlide uses rigid screws to fix the spine at the curve’s apex, and sliding screws above and below the apex that allow growth to continue. The FDA says the design allows the spine to continue growing and reduces the need for repeated lengthening surgeries until skeletal maturity. The system is based on Medtronic-licensed Shilla technology, which OrthoPediatrics said enabled it to develop VerteGlide. The FDA designated Medtronic’s SHILLA system as a primary predicate device for demonstrating substantial equivalence. It also concluded that the two systems were substantially equivalent and issued a Section 522 postmarket surveillance order to address potential concerns about wear debris. The order adds regulatory monitoring to the system’s post-approval path.
Surgical use preceded the current announcement: on April 8, 2025, OrthoPediatrics announced VerteGlide’s launch in the U.S. It said at the time that the system was the 80th it had developed to address musculoskeletal conditions in children. On September 10, 2025, the company announced the completion of the first U.S. surgeries using it to treat early-onset scoliosis. A pediatric orthopedic surgeon who took part in one of the first procedures said options for these patients were limited and that the system addressed an unmet clinical need. These milestones provide context on the transition from the system’s introduction to surgical use, but do not on their own confirm details of the commercial announcement issued on November 9. The available information also does not include the number of procedures or hospitals using the system.
The commercial follow-up comes as the company’s third-quarter 2026 results showed growth in its scoliosis segment. Segment revenue was $19.2 million, up 18% from $16.3 million in the third quarter of 2025, with the company attributing the increase to VerteGlide and Response. Companywide revenue reached a record $72.7 million, up 19% from $61.2 million in the year-earlier period. International revenue was $14.8 million, up 18% from $12.5 million, with the company attributing the growth mainly to a higher number of procedures. The results show sales expansion before the full commercial launch announcement, without specifying VerteGlide’s individual contribution to quarterly revenue. Performance in the segment and sales of the system in coming periods will therefore be important to understanding the breadth of its commercial impact.
Financial results also showed the net loss narrowing to $5.9 million in the third quarter of 2026, compared with $11.8 million a year earlier. Basic and diluted loss per share was $0.25, versus $0.50 in the third quarter of 2025. As of September 30, 2026, cash, short-term investments and restricted cash totaled $44.9 million, compared with $62.9 million on December 31, 2025. The figures do not show how much spending a broader launch may require or how it could affect liquidity. The company raised its 2026 revenue outlook to a range of $270 million to $273 million, from $265 million to $269 million previously. The revised outlook represents growth of between 14% and 16% from the prior year and is the latest available financial indication of what the company expects for the rest of the year.
OrthoPediatrics shares, listed under the ticker KIDS, closed at $31.76 on November 6, 2026. The available data do not include the stock’s trading range during that session or its price movement after the announcement published on November 9, so the close cannot be linked to a market reaction to the news. The key commercial question remains whether the announced launch will expand the system’s user base enough to support growth in scoliosis revenue following its quarterly results. The company’s near-term financial outlook runs through the end of 2026, with a revised revenue range of $270 million to $273 million. The information provided includes no company outlook for 2027 revenue or timeline for VerteGlide’s contribution to sales. The launch’s value will become clearer in future results if the company provides figures that break out the system’s performance or explain its rate of adoption.